For the Quarterly Period ended September 30, 2004

10QSB 1 d10qsb.htm FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2004 For the Quarterly Period ended September 30, 2004

United States

Securities and Exchange Commission

Washington D.C. 20549

Form 10-QSB

x	Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

For the Quarterly Period ended September 30, 2004

¨	Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Commission file number: 000-27866

VYREX CORPORATION

(Name of small business issuer as specified in its charter)

Nevada

88-0271109

(State or other jurisdiction of

incorporation or organization)

(IRS Employer

Identification No.)

2159 Avenida de la Playa, La Jolla, California, 92037

(Address of principal executive offices)

(858) 454-4446

(Issuer’s telephone number including area code)

Check whether the issuer (1) filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the past 12 months (or for shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No ¨

Applicable Only to Issuers Involved in Bankruptcy

Proceedings During the Preceding Five Years

Check whether the registrant filed all documents and reports required to be filed by Sections 12, 13 or 15(d) of the Exchange Act after the distribution of securities under a plan by a court. Yes ¨ No ¨

Applicable Only to Corporate Issuers

State the number of shares outstanding of each of the issuer’s classes of common equity, as of latest practicable date:

As of October 31, 2004, there are 8,492,867 shares of common stock outstanding and warrants to purchase 325,000 shares of common stock outstanding.

Transitional Small Business Disclosure Format Yes ¨ No x

Vyrex Corporation

Index to Form 10-QSB


Part I Financial Information

	Item 1 - Financial Statements
	Condensed Balance Sheets	3
	Condensed Statements of Operations	4
	Condensed Statements of Stockholders’ Equity (Deficiency)	5
	Condensed Statements of Cash Flows	8
	Notes to Condensed Financial Statements	9

	Item 2 - Management’s Discussion and Analysis of Financial Condition and Results of Operations	11

	Item 3 – Controls and Procedures	12

Part II Other Information		13

	Item 1 - Legal Proceedings	13

	Item 2 - Changes in Securities	13

	Item 3 - Defaults upon Senior Securities	13

	Item 4 - Submission of Matters to a Vote of Security Holders	13

	Item 5 - Other Information	13

	Item 6 - Exhibits and Reports on Form 8-K	13

Signatures		13

PART I Financial Information

Item 1. Financial Statements

Vyrex Corporation

(a development stage enterprise)

Condensed Balance Sheets


	Sep 30, 2004			Dec 31, 2003
	Unaudited			(Note 1)
Assets
Cash and cash equivalents	$	1,766		$	11,137
Accounts receivable		22,500			22,500

Total assets	$	24,266		$	33,637

Liabilities and stockholders’ deficiency
Current liabilities:
Accounts payable and accrued liabilities	$	82,470		$	82,707
Current portion of notes payable		7,500

Total current liabilities		89,970			82,707
Notes payable, net		197,500			196,000

Total liabilities		287,470			278,707


Commitments and contingencies

Stockholders’ deficiency:
Preferred stock, $.001 par value; 10,000,000 shares authorized; none issued		—			—
Common stock, $.001 par value; 50,000,000 shares authorized; 8,492,867 issued and outstanding		8,493			8,493
Additional paid-in capital		13,106,096			13,080,025
Deficit accumulated during the development stage		(13,377,793	)		(13,333,588	)

Total stockholders’ deficiency		(263,204	)		(245,070	)

Total liabilities and stockholders’ deficiency	$	24,266		$	33,637

See accompanying notes.

Vyrex Corporation

(a development stage enterprise)

Condensed Statements of Operations

(Unaudited)


	Three Months Ended September 30,						Nine Months Ended September 30,						Cumulative From Inception
	2004			2003			2004			2003			Cumulative From Inception
Licensing and royalty revenue	$	22,500		$	22,500		$	67,500		$	67,500		$	733,199

Operating expenses:
Research and development		10,644			9,334			14,657			11,604			6,471,116
Marketing and selling					298						298			438,664
General and administrative		15,347			23,304			80,479			109,440			6,176,548

Total operating expenses		25,991			32,936			95,136			121,342			13,086,328

Loss from operations		(3,491	)		(10,436	)		(27,636	)		(53,842	)		(12,353,129	)

Other income (expense):
Interest income		4			35			23			279			475,523
Loss on disposal of fixed assets		—			—			—			—			(13,664	)
Interest expense		(5,619	)		(5,541	)		(16,592	)		(15,202	)		(136,623	)
Charge from issuance of stock options for bridge financing		—			—			—			—			(1,349,900	)

Total other income (expense)		(5,615	)		(5,506	)		(16,569	)		(14,923	)		(1,024,664	)

Net loss	$	(9,106	)	$	(15,942	)	$	(44,205	)	$	(68,765	)	$	(13,377,793	)

Net loss per share – basic and diluted	$	(0.00	)	$	(0.00	)	$	(0.01	)	$	(0.01	)

Weighted-average number of common shares outstanding		8,492,867			8,492,867			8,492,867			8,492,867

See accompanying notes.

Vyrex Corporation

(a development stage enterprise)

Condensed Statements of Stockholders’ Equity (Deficiency)

(Unaudited)


	Common stock			Additional Paid-in Capital			Deficit accumulated during the development stage			Total stockholders’ equity (deficiency)
	Shares	Amount		Additional Paid-in Capital			Deficit accumulated during the development stage			Total stockholders’ equity (deficiency)
Issuance (at $.002 per share) for acquisition of technology retroactively reduced for 150,000 shares returned and retired on October 1, 1995	3,350,000	$	3,350	$	3,350		$	—		$	6,700
Issuance (at $.002 per share) for cash	500,000		500		500						1,000
Issuance (at $1.00 per share) for cash	800,000		800		799,200			—			800,000
Issuance as compensation (at $1.00 per share)	32,500		33		32,467			—			32,500
Issuance (at $2.00 per share) upon conversion of note payable	100,000		100		199,900			—			200,000
Issuance (at $3.00 per share) for cash, net of issuance costs of $4,086	33,000		33		94,881			—			94,914
Net loss	—		—		—			(1,085,932	)		(1,085,932	)

Balance at December 31, 1993	4,815,500		4,816		1,130,298			(1,085,932	)		49,182
Issuance (at $3.00 per share) for cash, net of issuance costs of $21,000	99,000		99		275,901			—			276,000
Issuance (at $3.00 per share) in lieu of finder’s fee	7,000		7		20,993			—			21,000
Issuance (at $3.00 per share) in lieu of finder’s fee	5,000		5		14,995			—			15,000
Issuance (at $3.00 per share) for cash, net of issuance costs of $41,844	24,990		25		33,101			—			33,126
Net loss	—		—		—			(467,683	)		(467,683	)

Balance at December 31, 1994	4,951,490		4,952		1,475,288			(1,553,615	)		(73,375	)
Issuance (at $3.00 per share) for cash, net of issuance costs of $46,976	149,940		150		402,694			—			402,844
Issuance (at $3.00 per share) in settlement of account payable	6,041		6		18,117			—			18,123
Issuance (at par value) as compensation for services related to prior issuances of common stock	83,000		83		(83	)		—			—
Issuance (at $3.00 per share) as compensation for services related to offering	13,334		13		39,989			—			40,002
Issuance (at $3.00 per share) of options for 450,000 shares as compensation for arranging bridge financing	—		—		1,349,900			—			1,349,900
Net loss	—		—		—			(1,854,584	)		(1,854,584	)

Balance at December 31, 1995	5,203,805		5,204		3,285,905			(3,408,199	)		(117,090	)
Proceeds from initial public offering (at $6.50 per unit), net of issuance costs of $1,135,453	1,057,097		1,057		5,734,620			—			5,735,677
Sale of option to purchase 300,000 shares (at $3.00 per share)	—		—		50,000			—			50,000
Exercise of stock options (at $3.00 per share) for cash	300,000		300		899,700			—			900,000
Conversion of notes payable and related accrued interest (at $3.00 per share)	86,015		86		257,959			—			258,045
Exercise of stock options (at $.00022 per share) for cash	450,000		450		(350	)		—			100
Issuance of units as compensation for legal services (at $4.55 per share)	24,292		24		110,505			—			110,529
Net loss	—		—		—			(1,820,614	)		(1,820,614	)

(Continued)

Vyrex Corporation

(a development stage enterprise)

Condensed Statements of Stockholders’ Equity (Deficiency)

(Unaudited)


	Common stock			Additional paid-in Capital		Deficit accumulated during the development stage			Total stockholders’ equity (deficiency)
	Shares	Amount		Additional paid-in Capital		Deficit accumulated during the development stage			Total stockholders’ equity (deficiency)
Balance at December 31, 1996	7,121,209	$	7,121	$	10,338,339	$	(5,228,813	)	$	5,116,647
Exercise of warrants, 200 shares at $8.00 per share	200		—		1,600		—			1,600
Warrants issued in conjunction with debenture offering	—		—		62,220		—			62,220
Net loss	—		—		—		(3,295,840	)		(3,295,840	)

Balance at December 31, 1997	7,121,409		7,121		10,402,159		(8,524,653	)		1,884,627
Issuance of stock as partial consideration for placement of debentures	8,000		8		49,992		—			50,000
Issuance of stock on conversion of debentures	227,222		227		807,414		—			807,641
Issuance of shares upon cashless exercise of stock options	66,824		67		396,513		—			396,580
Issuance of 375,000 stock options for services	—		—		87,000		—			87,000
Net loss	—		—		—		(3,388,412	)		(3,388,412	)

Balance at December 31, 1998	7,423,455		7,423		11,743,078		(11,913,065	)		(162,564	)
Issuance (at $.34 per share) for cash	119,412		120		40,480					40,600
Issuance of 47,000 stock options for services					6,580					6,580
Issuance of 250,000 warrants for services					30,500					30,500
Net loss							(788,548	)		(788,548	)

Balance at December 31, 1999	7,542,867		7,543		11,820,638		(12,701,613	)		(873,432	)
Forgiveness of accrued compensation					422,559					422,559
Issuance (at $.90 per share) for cash	300,000		300		269,700					270,000
Exercise of stock options (at $.10 per share) for cash	250,000		250		24,750					25,000
Exercise of warrants (at $.10 per share) for cash	100,000		100		9,900					10,000
Issuance (at $1.00 per share) for cash	150,000		150		149,850					150,000
Reduction of exercise price for options and warrants					148,000					148,000
Net loss							(335,487	)		(335,487	)

Balance at December 31, 2000	8,342,867		8,343		12,845,397		(13,037,100	)		(183,360	)
Issuance of 50,000 stock options for services					18,500					18,500
Issuance of 200,000 warrants for services					50,000					50,000
Net loss							(202,185	)		(202,185	)

(Continued)

Vyrex Corporation

(a development stage enterprise)

Condensed Statements of Stockholders’ Equity (Deficiency)

(Unaudited)


	Common stock			Additional paid-in capital		Deficit accumulated during the development stage			Total stockholders’ equity (deficiency)
	Shares	Amount		Additional paid-in capital		Deficit accumulated during the development stage			Total stockholders’ equity (deficiency)
Balance at December 31, 2001	8,342,867	$	8,343	$	12,913,897	$	(13,239,285	)	$	(317,045	)
Modification of stock options					2,000					2,000
Issuance of stock upon exercise of warrants at $.10 per share	150,000		150		14,850					15,000
Forgiveness of accrued compensation					140,978					140,978
Issuance of 20,000 warrants for services					2,000					2,000
Issuance of 5,000 warrants for services					300					300
Net loss							(3,763	)		(3,763	)

Balance at December 31, 2002	8,492,867		8,493		13,074,025		(13,243,048	)		(160,530	)
Issuance of 100,000 warrants in connection with debt issuance					6,000					6,000
Net loss							(90,540	)		(90,540	)

Balance at December 31, 2003	8,492,867		8,493		13,080,025		(13,333,588	)		(245,070	)
Forgiveness of accrued compensation					26,071					26,071
Net loss							(44,205	)		(44,205	)

Balance at September 30, 2004	8,492,867	$	8,493	$	13,106,096	$	(13,377,793	)	$	(263,204	)

See accompanying notes.

Vyrex Corporation

(a development stage enterprise)

Condensed Statements of Cash Flows

(Unaudited)


	Nine Months ended						Cumulative From Inception
	Sep 30, 2004			Sep 30, 2003			Cumulative From Inception
Operating activities
Net loss	$	(44,205	)	$	(68,765	)	$	(13,377,793	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation, amortization and impairment charges								336,329
Accretion of debt discount		1,500			1,500			3,500
Interest receivable								3,506
Loss on disposal of fixed assets								13,664
Issuance of compensatory notes, stock, stock options and warrants								2,302,512
Changes in operating assets and liabilities:
Accounts receivable and other assets					57,500			77,500
Accounts payable and accrued liabilities		25,834			(14,586	)		672,082
Deferred revenue								(100,000	)
Accrued interest on convertible debentures								9,041

Net cash used in operating activities		(16,871	)		(24,351	)		(10,059,659	)

Investing activities
Purchase of short-term investments								(8,440,442	)
Sale of short-term investments								8,467,931
Purchases of fixed assets								(209,595	)
Proceeds on sale of fixed assets								10,000
Patent, trademark and copyrights costs								(133,519	)
Other assets, including notes receivable from related parties								(4,202	)

Net cash used in investing activities								(309,827	)

Financing activities
Net proceeds from issuance of common stock								7,889,808
Exercise of stock options and sale of options								975,100
Exercise of warrants								25,000
Proceeds from short-term loan								867,730
Proceeds from note payable		7,500			200,000			798,614
Repayment of note payable					(165,000	)		(185,000	)
Advances from potential investors								100,000
Repayment of advances								(100,000	)

Net cash provided by financing activities		7,500			35,000			10,371,252

Net increase (decrease) in cash and cash equivalents		(9,371	)		10,649			1,766
Cash and cash equivalents, beginning of period		11,137			3,026			—

Cash and cash equivalents, end of period	$	1,766		$	13,675		$	1,766

Supplemental disclosure of non cash financing activity:
Forgiveness of accrued compensation	$	26,071					$	589,608

See accompanying notes.

Vyrex Corporation

(A Development Stage Enterprise)

Notes To Condensed Financial Statements

(Unaudited)

(1) Basis of Presentation

The accompanying condensed financial statements have been prepared by the Company in conformity with accounting principles generally accepted in the United States of America for interim financial information. Certain information and disclosures normally included in financial statements prepared in conformity with accounting principles generally accepted in the United States of America have been condensed or omitted. In the opinion of the Company’s management, the unaudited financial statements contain all adjustments necessary (consisting of normal recurring accruals) for a fair presentation of the Company’s financial position as of September 30, 2004, and its results of operations and cash flows for the three and nine-month periods ended September 30, 2004 and 2003 and for the period from inception through September 30, 2004. The results of operations for the three and nine-month periods ended September 30, 2004 are not necessarily indicative of the results to be expected for the full year. For further information, refer to the financial statements and notes thereto included in Vyrex’s Form 10-KSB for the year ended December 31, 2003.

The accompanying condensed financial statements have been prepared assuming that the Company will continue as a going concern. This basis of accounting contemplates the recovery of the Company’s assets and the satisfaction of its liabilities in the normal course of business. As of September 30, 2004, the Company had an accumulated deficit of $13,377,793, a stockholders’ deficiency of $263,204 and negative working capital of $65,704. Due to the Company’s recurring losses and stockholders’ deficiency, there can be no assurance that the Company will be able to obtain additional operating capital, which may impact the Company’s ability to continue as a going concern. The accompanying condensed financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the possible inability of the Company to continue as a going concern.

The Company continues to seek additional collaborative or other arrangements with larger pharmaceutical and nutraceutical companies, under which such companies would provide additional capital to the Company in exchange for exclusive or non-exclusive licenses or other rights to certain of the technologies and products the Company is developing. Competition for corporate partnering arrangements with major pharmaceutical and nutraceutical companies is intense, with a large number of biopharmaceutical companies attempting to arrive at such arrangements. Accordingly, there can be no assurance that an agreement will arise in a timely manner, or at all, or that any agreement that may be reached will successfully reduce the Company’s short-term or long-term funding requirements.

The Company’s major activities through September 30, 2004 have consisted of seeking additional licensing opportunities for its intellectual properties and joint ventures to market its nutraceutical products and initiating the research necessary to take its drug candidates forward into clinical trials. Currently, a major focus for the Company is the testing of its proprietary ProFlavone technology. ProFlavones are proprietary nutraceuticals being developed by the Company for cardiovascular, skeletal and cellular health. ProFlavones are novel delivery forms of isoflavones. Isoflavones are chemicals (phytochemicals) found in beans, particularly soy. Isoflavones are antioxidants and possess estrogenic activity (phytoestrogens) and are thought to have anti-atherogenic, anti-carcinogenic and anti-osteoporotic activities as well. Recently, some isoflavones have also been shown to be protective against ionizing radiation (radioprotectants). Radioprotectants have application in oncology, space travel, radiological terrorism and military scenarios. The Company has synthesized and is testing a number of its isoflavone prodrug forms covered under U.S. Patent Number 6,541613 and U.S. Patent Application 20030212009. A high priority for the Company is the

testing of its ProFlavones for radioprotective activity. On September 5, 2004 the Company announced that it was proceeding with its plans to use its antioxidant and prodrug technologies to develop radioprotective agents against nuclear/radiologic terrorism. The first such agent, GEN-VYX1-2004, has been synthesized, has undergone initial animal toxicity studies and found to be non-toxic. The Company continually works toward raising funds for outsourcing research and development on its novel technology, seeking additional collaborative partners through exclusive or non-exclusive licensing of its technology and continuing to work with its current partners to generate additional revenues based on existing licensing and royalty agreements. These activities have not generated any significant revenues; accordingly, the Company has been in the development stage since its inception. Successful completion of the Company’s development program and its transition, ultimately, to attaining profitable operations is dependent upon obtaining additional financing adequate to fulfill its research and development activities, and achieving a level of revenue adequate to support the Company’s cost structure. There can be no assurance that the Company will be successful in these areas. To supplement its existing resources, the Company will require additional capital through the sale of debt or equity. There can be no assurance that such capital will be available on favorable terms, or at all, and if additional funds are raised by issuing equity securities, dilution to existing stockholders is likely to result.

(2) Notes Payable

During March 2003, the Company obtained a note from a private investor to loan the Company $200,000 in the form of a convertible note at an interest rate of 10% per annum. Interest is paid quarterly with the principal due and payable at the end of the third year. The note is collateralized by substantially all of the assets of the Company. The investor had the option to convert the principal amount into Vyrex common shares at a price of $0.25 during the first year, $0.50 the second year and $0.75 the third year. Further in connection with the Promissory Note, the investor was issued warrants, exercisable within three years from the date of issuance, entitling the investor to purchase Vyrex Corporation common shares in the amount of 100,000 shares at an exercise price of $0.11 per share. The warrants had a fair value of $6,000 as of the date of issuance; accordingly, the Company discounted the note by $6,000 which was added to additional paid-in capital. The Company is accreting the discount on a straight-line basis over the term of the note. The Company has recognized $1,500 additional interest expense related to the accretion of this debt discount for the period ended September 30, 2004. On August 24, 2004 the Company obtained an additional note from the same private investor in the amount of $7,500. The principal amount plus 10% interest is due and payable on February 24, 2005. As further consideration for the loan the Company agreed to amend the strike price terms of the right to convert the principal amount of the March 2003 note into Vyrex common shares from $0.50 to $0.25 the second year and from $0.75 to $0.50 the third year.

(3) Stock-Based Compensation

As explained in Note 8 in the Form 10-KSB, the Company accounts for stock options granted to employees based on their intrinsic values under the recognition and measurement principles of APB Opinion No. 25, “Accounting for Stock Issued to Employees, and Related Interpretations”, and has adopted the disclosure-only provisions of Statement of Financial Accounting Standards (SFAS) No. 123, “Accounting for Stock-Based Compensation”, and the provisions of Statement of Financial Accounting Standards No. 148, “Accounting for Stock-Based Compensation-Transition and Disclosure-an amendment of FASB Statement No. 123”. Since the exercise price of all of the options granted by the Company to its employees has been equal to or greater than fair value, the Company has not recognized any earned or unearned compensation costs in its financial statements in connection with those options. The Company’s historical net loss and basic net loss per share, and pro forma net loss and basic net loss per share, for the three and nine months ended September 30, 2004 and 2003 assuming compensation cost had been determined based on the fair value of all options at the respective dates of grant determined using a pricing model consistent with the provisions of SFAS 123 are set forth below:


	Three Months Ended September 30,						Nine Months Ended September 30,
	2004			2003			2004			2003
Net loss - as reported	$	(9,106	)	$	(15,942	)	$	(44,205	)	$	(68,765	)

Stock-based employee compensation expense assuming a fair value based method had been used for all awards		(4,000	)		(13,313	)		(12,000	)		(39,938	)

Net loss – pro forma	$	(13,106	)	$	(29,255	)	$	(56,205	)	$	(108,703	)

Basic loss per share – as reported	$	(.00	)	$	(.00	)	$	(.01	)	$	(.01	)

Basic loss per share – pro forma	$	(.00	)	$	(.00	)	$	(.01	)	$	(.01	)

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

This report on Form 10-QSB contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. The Company intends that such forward-looking statements be subject to the safe harbors created thereby. This report should be read in conjunction with the Company’s annual report on Form 10-KSB for the year ended December 31, 2003.

Results of Operations

Three months ended September 30, 2004 and September 30, 2003

Licensing and royalty revenue remained the same at $23,000 for the three months ended September 30, 2004 and 2003. Royalty revenue is comprised of our boron compound licensed by the FutureCeuticals Division of Van Drunen Farms.

General and administrative expenses decreased $8,000 to $15,000 in the current period, compared to $23,000 for the same period in 2003. Third quarter expenses were limited to maintenance of patents and general office expenses such as accounting fees, utility expenses, telephone expenses, rent and postage. Research and development expenses increased $2,000 to $11,000 in the current period, compared to $9,000 for the same period in 2003. Research and development expenses consisted of royalty expenses for our Boron patent and for purchased services.

Net loss decreased $7,000 to $9,000 in the current period, compared to $16,000 for the same period during 2003. Basic and diluted loss per share remained the same at $0.00 in the three months ended September 30, 2004 and 2003.

Nine months ended September 30, 2004 and September 30, 2003

Royalty revenue remained the same at $68,000 for the nine months ended September 30, 2004 and 2003. Royalty revenue for this period was comprised of our boron compound licensed by the FutureCeuticals Division of Van Drunen Farms. Royalty revenue for carnochrome is no longer received due to the March 2004 termination elected by FutureCeuticals based on the terms of the license agreement.

General and administrative expenses decreased $29,000 to $80,000 in the current period, compared to $109,000 for the same period in 2003. Expenses were limited to maintenance of patents and general office expenses such as accounting fees, utility expenses, telephone expenses, rent and postage. Research and development expenses increased $3,000 to $15,000 in the current period, compared to $12,000 for the same period in 2003. Research and development expenses consisted of royalty expenses for our Boron patent and for purchased services.

Net loss decreased $25,000 to $44,000 in the current period compared to $69,000 for the same period during 2003. Basic and diluted loss per share remained the same at $0.01 in the nine months ended September 30, 2004 and 2003.

Liquidity and Capital Resources

The Company has financed its operations since inception solely through the sales of debt and equity securities. As of September 30, 2004, the Company had negative working capital of $66,000. Net cash used in operating activities during the nine months ended September 30, 2004 was $17,000, compared to net cash used by operating activities of $24,000 for the same period during 2003.

There can be no assurance that any further revenues will be realized in 2004 or that they will be significant and therefore without additional financing the Company may be unable to continue as a going concern. The Company is actively pursuing collaborations with potential partners in both the pharmaceutical and nutraceutical divisions with the objective of raising financing to enable the Company to continue operations. At September 30, 2004, the Company does not have any commitments for additional financing and has no prospects for merger or acquisition. The Company does not have any lease or other commitments. The Company does not have an existing bank line of credit or other form of revolving or renewable credit facility. There can be no assurance the Company will generate significant revenues during 2004 to continue its operations, or that funds will be available through the public or private markets.

The Company believes but cannot assure that its current cash reserves and other resources will fund the business through at least September 30, 2005. The Company does not anticipate having significant revenues in the foreseeable future and will likely be required to raise additional funds to continue operations. There can be no assurance that additional funds will be available.

Item 3. Controls and Procedures

As of September 30, 2004, the Company carried out an evaluation under the supervision and with the participation of the Company’s management, including the Company’s Chief Executive Officer and President, of the effectiveness of the design and operation of the Company’s disclosure controls and procedures pursuant to Rule 13a-14 of the Securities Exchange Act of 1934. Based upon that evaluation, the principal executive officer concluded that the Company’s disclosure controls and procedures are effective in timely alerting them to material information relating to the Company, required to be included in the Company’s periodic SEC filings. There were no significant changes in internal controls or in other factors that could significantly affect internal controls subsequent to the date of our most recent evaluation.

PART II Other Information

Item 1. Legal Proceedings

Not applicable

Item 2. Changes in Securities

Not applicable

Item 3. Defaults upon Senior Securities

Not applicable

Item 4. Submission of Matters to a Vote of Security Holders

Not applicable

Item 5. Other Information

Not applicable

Item 6. Exhibits and Reports on Form 8-K

(a) Exhibits

Exhibit 31.1 – Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

Exhibit 32.1 – Certification of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

(b) Reports on Form 8-K

None

SIGNATURES

In accordance with Section 13 or 15(d) of the Exchange Act, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.


VYREX CORPORATION
Registrant

By:		/S/ G. Dale Garlow
		G. Dale Garlow,
		Chief Executive Officer